“Armed” oncolytic herpes simplex virus enables CD19/BCMA CAR-T for solid tumor treatment as a combination therapy

Calendar Icon - Evently Webflow Template
12 Oct
Clock Icon - Evently Webflow Template

About the Session

  1. oHSV MVR-T7 series was genetically engineered to drive ectopic expression of the extracellular domain of CD19/BCMA.
  2. Co-culture studies were performed to test the cell-killing activity of CD19/BCMA CAR-T combined with T7.
  3. Antitumor activities of T7011 administrated via intratumoral (IT) or intraperitoneal (IP) in combination with CD19 CAR-T cells were assessed in immunodeficient and immunocompetent mice.
Are you ready?

Get Early Access to
BioCon Asia-ACGT Conference!